Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Retained Earnings came in at -$384.2 million in Q1 2026, down 468400.0% YoY from N/an in Q1 2025, and up 8.98% on a QoQ basis from -$422.1 million in Q4 2025.
Zevra Therapeutics (ZVRA) Retained Earnings (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Retained Earnings data on file, last reported at -$384.2 million in Q1 2026.
- Quarterly Retained Earnings fell 468400.0% year-over-year to -$384.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$384.2 million (down 468400.0% YoY) and the FY2025 annual result came in at -$422.1 million, down 66987.48% from the prior year.
- Retained Earnings advanced to -$384.2 million in Q1 2026, from -$422.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $631000.0 in Q4 2024 to a low of -$469.6 million in Q3 2024.
- A 5-year average of -$268.2 million and a median of -$346.1 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.16% — and 2026, when it plunged 468400.0%.
- Tracing ZVRA's Retained Earnings over 5 years: stood at -$353.7 million in 2022, then slipped by 13.02% to -$399.8 million in 2023, then jumped by 100.16% to $631000.0 in 2024, then sank by 66987.48% to -$422.1 million in 2025, then grew by 8.98% to -$384.2 million in 2026.
- The last three Retained Earnings figures came in at -$384.2 million (Q1 2026), -$422.1 million (Q4 2025), and -$434.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | -375.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -375.42 Mn |
| Mar 31, 2026 | -384.17 Mn |
| Dec 31, 2025 | -422.06 Mn |
| Sep 30, 2025 | -434.23 Mn |
| Jun 30, 2025 | -433.68 Mn |
| Mar 31, 2025 | -82,000.00 |
| Dec 31, 2024 | 631,000.00 |
| Sep 30, 2024 | -469.60 Mn |
| Jun 30, 2024 | -436.33 Mn |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | -399.78 Mn |
| Sep 30, 2023 | -220,000.00 |
| Jun 30, 2023 | -225,000.00 |
| Mar 31, 2023 | -320.34 Mn |
| Dec 31, 2022 | -353.73 Mn |
| Sep 30, 2022 | -299.55 Mn |
| Jun 30, 2022 | -338.44 Mn |
| Sep 30, 2021 | -264.33 Mn |
| Jun 30, 2021 | -262.57 Mn |
| Mar 31, 2021 | -268.77 Mn |